SGB-3383

SGB-3383 is an investigational small interfering RNA (siRNA) therapeutic developed to target complement factor B (CFB), thereby modulating the alternative pathway of the complement system. Its primary focus is the treatment of complement-mediated kidney diseases and related systemic conditions. By silencing the CFB gene, SGB-3383 aims to reduce the aberrant complement activation implicated in diseases such as IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), and atypical hemolytic uremic syndrome (aHUS). The drug has entered Phase 1 clinical trials, following regulatory approval in China to begin clinical evaluation for these indications. Its anticipated mechanism offers a best-in-class potential for controlling complement-mediated pathologies[1][3][9][10].